Research and Markets (http://www.researchandmarkets.com/research/6b7faa/innovative_drug_r) has announced the addition of the "Innovative Drug R&D in China" report to their offering.
As Chinese pharmaceutical industry is rising rapidly, a growing number of Chinese drug companies pay attention to investing in research of innovative medicines. Their attempts are encouraged by government who promises to provide financial support and improve industry infrastructure. Their programs are infused with increasing numbers of returnees. Their progress is also accelerated by the growing abundance of venture capitals.
Their efforts have now started yielding fruitful results. There have been a variety of drug candidates in various development stages in the product pipelines of these Chinese drug companies for a broad range of therapeutic targets. More significantly, driven by a number of positive factors, this sector of the Chinese pharmaceutical industry has gained an extraordinary growth momentum and will thus continue to develop in the future.
However, to a large extent, it is still a myth to many companies/organizations outside China about the R&D activities in these Chinese drug companies and the progress of their programs.
The report "Innovative Drug R&D in China" is designed to reveal the real state of the innovative drug R&D in China including their research scope and scale, their current focus and capability in innovative drug R&D and the development stage of their product pipelines.
Based on a broad and in-depth investigation, the report provides a clear insight into the current situation of the innovative drug R&D in China. It also provides the in-depth analysis of the future growth potential and drivers of this Chinese industry.
The report is a must-read book to global pharmaceutical and biotech companies that are seeking research collaborations with Chinese companies, venture capital investors interested in investment opportunities in Chinese pharmaceutical and biotech industries, market research/consultancy companies seeking the information of the development situation of China's drug R&D, and even the government agencies of those countries that are interested in learning the current and future development of China's biotech industry.
Key Findings of the Report